The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency

Table 2

Change in iron and blood cell parameters after the first iron isomaltoside treatment.

	Pretreatment	Posttreatment	Concentration change	value^a	Time of evaluation^b
Mean (SD)
Hb, g/dL; ()^c	10.5 (1.5)	12.5 (1.4)	2.0 (1.4)	<0.0001	7.1 (6.0)
TSAT, %; ()^d	9.6 (6.5)	21.0 (9.8)	11.4 (10.0)	<0.0001	7.6 (5.0)
Ferritin, μg/L	25.0 (68.0)	146.3 (173.1)	121.3 (162.6)	<0.0001	7.4 (6.5)
Median (IQR)^e; ()^d	10.0 (6.0–20)	95.0 (49–181)	71.0 (35–157)

^a values for concentration changes obtained by analysis of covariance test with diagnosis and dose as factors and pretreatment laboratory parameter concentration as covariate. ^bTime (weeks) between the last administration of first iron isomaltoside treatment and blood test follow-up. ^cAnaemic patients (Hb < 13 g/dL for men and Hb < 12 g/dL for women at baseline) with available pre- and posttreatment Hb measures in the total population. ^dPatients with available pre- and posttreatment laboratory measures in the total population. ^eMedian is presented for data not normally distributed. Hb: haemoglobin; IQR: interquartile range; SD: standard deviation; TSAT: transferrin saturation.